EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 697 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Celebrating 10 years of partnership with ScottishPower and £35m raised June 16, 2022 GreaterGood’s Mask Donations Are Helping LA Family Housing Keep Homeless People... October 26, 2020 Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in... October 19, 2023 Blind Man Overcomes Life Of Struggles & Becomes An Incredible Woodworker November 23, 2021 Load more HOT NEWS New Vaccine Stimulates Survivors’ Immune Systems to Keep Triple-Negative Cancer from... 2021 ASCO Annual Meeting: Immunotherapy for Melanoma and Non-Small Cell Lung Cancer,... Mental Health Awareness for Health Care Providers PD1 and LAG3 Inhibition Plus Chemoradiotherapy in the Neoadjuvant Setting for...
